Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG1LVA)

• Drug Name: BLZ-945 Drug Info
• Synonyms: CSF-1R inhibitor (bone cancer); CSF-1R inhibitor (bone cancer), Novartis

Indication

Disease Entry	ICD 11	Status	REF
Amyotrophic lateral sclerosis	8B60.0	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 46184986
  CAS Number: CAS 953769-46-5
  TTD Drug ID: DMG1LVA

Molecule-Related Drug Atlas

Drug(s) Targeting Macrophage colony-stimulating factor 1 receptor (CSF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[4]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[2]
ARRY-382	DM0VGDC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Cabiralizumab	DMGE058	Pancreatic cancer	2C10	Phase 2	[5]
AMB-05X	DM958C5	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[6]
FPA-008	DM3ZN6Y	Autoimmune diabetes	5A10	Phase 1/2	[7]
DCC-3014	DMHW289	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
DCC-3014	DMHW289	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[2]
TPX-0022	DMC2IJN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]

Drug(s) Targeting Granulocyte colony-stimulating factor receptor (G-CSF-R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tbo-Filgrastim	DML6OE7	Neutropenia	4B00.0	Approved	[10]
Pegfilgrastim	DM7UP8X	Central nervous system neoplasm		Approved	[11]
Peg-G-CSF	DMBKWAF	Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]
SBC-014	DMG1VXR	Neutropenia	4B00.0	Phase 2	[12]
AX-200	DMTAEMB	Cardiovascular disease	BA00-BE2Z	Phase 2	[13]
MAXY-G34	DMWLIPJ	Neutropenia	4B00.0	Phase 2	[14]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[15]
AMG 820	DMB6Q19	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
MK-6302	DMZUA5C	Neutropenia	4B00.0	Phase 1	[16]
PLX-5622	DMK4PWM	Autoimmune diabetes	5A10	Phase 1	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Granulocyte colony-stimulating factor receptor (G-CSF-R)	TTC70AJ	CSF3R_HUMAN	Inhibitor	[3]
Macrophage colony-stimulating factor 1 receptor (CSF1R)	TT7MRDV	CSF1R_HUMAN	Antagonist	[2]

References

• [1] ClinicalTrials.gov (NCT04066244) Study of Safety and of the Mechanism of BLZ945 in ALS Patients. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of AmMax Bio
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [9] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [10] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [11] Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8.
• [12] A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9: 2.
• [13] Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013 Oct;44(10):2681-7.
• [14] Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38.
• [15] National Cancer Institute Drug Dictionary (drug id 747694).
• [16] Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.
• [17] Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol Med. 2012; 18(1): 519-527.